Inovio Pharma (INO)
$1.89
0.10 (5.03%)
INO Stock Quote Delayed 30 Minutes
INO Stock Plunges 25% as Inovio Pharmaceuticals Swaps Vaccine Focus
Inovio Pharmaceuticals has halted its Covid-19 progress to focus on a booster. Here's why this news is unlikely to boost INO stock.
11 Best Stocks to Buy for 2022
He found Apple at $1.49... Oracle at $0.51... Amazon at $46. Now, investing legend Louis Navellier is revealing his Top 11 Stocks for 2022 — FREE!
Download His Free Report Here:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Unlock Louis Navellier's
? Stock Report – FREE:
Is ? a BUY?
Powered by Portfolio Grader
A
B
C
D
F
?
Unlock Louis Navellier's
? Stock Report to Find Out – FREE:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Investing legend Louis Navellier rates ? a "?." Unlock his ? Stock Analysis to find out why – FREE:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Fundamental Grade
Quantitative Grade
- Sales Growth ?
- Operating Margin Growth ?
- Earnings Growth ?
- Earnings Momentum ?
- Earnings Surprises ?
- Analyst Earnings Revisions ?
- Cash Flow ?
- Return on Equity ?
Previous Close
-
Market Cap
397.57M
PE Ratio
-1.82
EPS
-1.04
Volume (Avg. Vol.)
5.15M
Day's Range
$1.87 - $2.04
52-Week Range
$1.60 - $10.33
Dividend & Yield
N/A (N/A)
INO Stock Predictions, Articles, and Inovio Pharma News
INO Stock: 2 Big Reasons Inovio Pharmaceuticals Is Shooting Higher Today
Today, INO stock is soaring amid a recently announced expanded partnership for its Covid-19 vaccine and potential short squeeze implications.
I Would Hope Inovio Isn’t Attracting ANY Serious Money
A recent article wondered if the smart money preferred Ocugen or Inovio. I would hope neither INO stock or OCGN is getting any serious money.
4 Top Stock Trades for Monday: SNAP, INTC, HON, INO
Snap, Intel, Honeywell and Inovio were our top stock trades for Monday. That said, let's look at how the charts are setting up now.
Sell Inovio While You Still Can
INO stock is poised to fall further as the chances of a vaccine approval fall and its competitors widen their lead
Don’t Sleep on Inovio Pharmaceuticals as a Serious Vaccine Contender
When will INO stock finally turn a corner? That's a question on some investor's minds, and recent data suggests a turnaround might be afoot.
Reality Hits Home for Shares of Inovio Pharmaceuticals
Shares of INO stock is being held back by a delayed clinical trial for Inovio’s vaccine candidate to combat the coronavirus.
Just Say No to Inovio Pharmaceuticals Stock
While INO stock has boasted a banner year, Inovio appears no closer to a Covid-19 vaccine than any of the other 150 contenders.
Count on the Advancement of DNA Medicine with Inovio Stock
If you're thinking that INO stock is just a wager on a Covid-19 vaccine candidate, think again. Inovio's pipeline is robust and diverse.
Prepare for Phase 2 and a Comeback for Inovio
Is INO stock nothing more than a post-pandemic pop-and-drop story? Don't count Inovio out as a crucial funding source offers timely support.
Inovio Gets the Go-Ahead But It’s Probably Too Late
Inovio got the go-ahead from the FDA on Nov. 16 to resume its Phase 2 clinical trial. Is INO stock worth betting on this late in the game?
Inovio Pharmaceutical’s FDA Plight Makes It a Highly Risky Bet
INO stock has tumbled in the past few months. Inovio needs the FDA to bail it out by allowing the advanced trials of its vaccine to begin.
The Clock Is Ticking for Inovio Stock
The FDA recently lifted the clinical hold on Inovio's Covid-19 vaccine candidate. The result could mean huge returns for INO stock.
Inovio Has Little to Show for Its Covid-19 Efforts
Inovio Pharmaceuticals has little to show for its Covid-19 efforts. INO stock is not worth more than $2, according to one short-seller.
At This Point, Go Ahead and Count Inovio Pharmaceuticals Out of the Vaccine Race
INO stock is a purely speculative bet. I don't see the company being among the few that deliver a vaccine against Covid-19.
Can Inovio Benefit From All Of Its Vaccine Delays?
Shares of Inovio (NASDAQ:INO) are trading near a six-month low. The company is being battered by delays in getting its Covid-19 vaccine candidate into Phase....
Avoid Taking a Bet on the Deep Correction In Inovio Stock
Small-cap biotechs are inherently challenging. With a failed INO-4800 timeline, INO stock increasingly finds itself back in this group.
